Pfizer, Johnson & Johnson, Merck: 10 Pharma Stocks Hedge Funds Love

After identifying the ten most popular stocks among hedge funds according to their third quarter 13F filings, we have decided to break down the top ten stocks that hedge funds love in the pharmaceutical industry. Our list includes the hundreds of hedge funds and prominent investors that are required by the SEC to disclose their public equity holdings quarterly. In descending order, we have outlined the most-loved healthcare stocks based on the aggregate number of funds owning each.

DUQUESNE CAPITAL

Medicis Pharmaceutical Corp (NYSE:MRX) was the 10th most popular pharma stock among hedge funds during 3Q, with 32 funds holding interest. The net increase in filers was three, the most of our ten stocks listed. Medicis is up over 30% year to date. Driving Medicis higher has been a buyout offer by Valeant Pharmaceuticals. The buyout was for $44 per share and valued Medicis at $2.6 billion. Even with the premium on its shares, the company still trades in line with its peers on a valuation basis at around 30x earnings.

Celgene Corporation (NASDAQ:CELG) was the ninth most popular pharma stock, seeing a net decrease of eight filers, the largest decrease of all ten pharma stocks listed. Celgene is a biopharma company, but trades in line with the much larger pharma stocks at 21x earnings, such as Johnson & Johnson and Pfizer. Trading at 14x forward earnings and having a 22% expected EPS annual growth rate, it appears that Celgene is a good buy.

Eli Lilly & Co. (NYSE:LLY) saw 37 hedge funds owning shares, putting it at eighth on our list. Eli trades on the very low end of the industry at 13x earnings, while also paying a 4%+ dividend. Eli is down almost 10% over the last month on a 3Q earnings miss, but is expected to grow earnings next year by 10%. We see Eli as a good value, with one of the more solid dividends in the industry.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) filled the seventh position with 38 filers owning the pharma company at the end of 3Q. Valeant trades at an almost 300x P/E after a pop in the stock on the news it would acquire the 10th most popular pharma stock among hedge funds, Medicis. The acquisition will be a driving force behind its five-year expected earnings CAGR of 15%. Despite the stock’s high P/E, we believe the combined companies will be able to recognize cost synergies that might not be fully reflected in its expected growth rate.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) saw a net decrease of five filers from 2Q and had 39 funds owning the stock at the end of 3Q, making it the sixth most popular. Teva is relatively flat on the year, and appears to be mediocre from a valuation standpoint. The pharma company trades at a 16x P/E and is expected to grow 5-year EPS at only 8%. Worth keeping an eye on is whether Teva can make a play for Amarin, which would then change our thesis on the company.

Abbott Laboratories (NYSE:ABT), the fifth most popular pharma stock among hedge funds, saw 47 filers holding ownership at the end of the third quarter. Like Teva, the company has a mediocre P/E at 16x, but Abbott pays a 3% dividend yield and has a solid five-year expected earnings growth rate of 9%. Abbott has a strong product portfolio and a 0.3 beta that gives it an advantage over the other pharma stocks listed so far. Abbott is a Diamond Hill top pick.

Sanofi SA (NYSE:SNY) called 52 hedge funds as owners and came in at fourth on our list. Sanofi appears mediocre on the surface with a 16x trailing P/E and a 2% expected five-year earnings growth rate, but its 3.7% dividend is where the stock stands out. Sanofi’s dividend is only a 60% payout on earnings, and with $4 billion in cash on hand, the company could easily boost its yield going forward.

Merck & Co., Inc. (NYSE:MRK) only slightly outpaced Sanofi for third place with 53 hedge funds owning the stock at the end of last quarter. Trading at 20x trailing earnings, Merck is in line with other $100+ billion market cap pharma companies, but looking at Merck’s 12x forward P/E suggests the company is a value play. Its 3.8% dividend yield is one of the highest of our major pharma stocks listed. Merck is one of billionaire Stanley Druckenmiller’s top five stock picks.

Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) were miles above the other pharma companies when it came to the number of filers owning their shares. Johnson & Johnson came in at a close second with 71 filers, while Pfizer was the top stock owned with 73 funds invested.

Investors appear to be over discounting Johnson & Johnson’s earnings for next year, where the company trades at 23x trailing earnings, but only 13x forward earnings. Pfizer trades in a similar scenario as Johnson & Johnson, with a trailing P/E in line with the industry at 19x, but with a heavily discounted forward P/E of 11x. Both pharma companies appear to be solid investments, each having a diverse product portfolio and operating internationally. Johnson & Johnson pays a dividend that yields 3.5%, and Pfizer pays a 3.6% yield.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 9 Most Dangerous Countries for Tourists to Visit

Reign of Terror: The 10 Most Ruthless Politicians in History

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!